InstitutionMD Anderson
Address2130 W Holcombe Blvd
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy. Clin Cancer Res. 2024 Mar 12. PMID: 38470545.
      Citations:    Fields:    
    2. Bossuyt V, Provenzano E, Symmans WF, Webster F, Allison KH, Dang C, Helenice G, Kulka J, Lakhani SR, Moriya T, Quinn CM, Sapino A, Schnitt S, Sibbering DM, Slodkowska E, Yang W, Tan PH, Ellis I. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 2024 Mar 05. PMID: 38443320.
      Citations: 1     Fields:    
    3. Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740. PMID: 38109213; PMCID: PMC10956403.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 Jan 18. PMID: 38236702.
      Citations:    Fields:    
    5. Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F, Yazdani A. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy. Res Sq. 2023 Dec 15. PMID: 38168324; PMCID: PMC10760223.
    6. Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Copp? JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Rep Med. 2023 12 19; 4(12):101312. PMID: 38086377; PMCID: PMC10772394.
      Citations:    Fields:    Translation:Humans
    7. Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Netw Open. 2023 Dec 01; 6(12):e2349646. PMID: 38153734; PMCID: PMC10755617.
      Citations:    Fields:    Translation:HumansCells
    8. Rediti M, Fernandez-Martinez A, Venet D, Roth? F, Hoadley KA, Parker JS, Singh B, Campbell JD, Ballman KV, Hillman DW, Winer EP, El-Abed S, Piccart M, Di Cosimo S, Symmans WF, Krop IE, Salgado R, Loi S, Pusztai L, Perou CM, Carey LA, Sotiriou C. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nat Commun. 2023 11 03; 14(1):7053. PMID: 37923752; PMCID: PMC10624889.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso M, Yuan Y, Abbattista A, Noonan K, Niyazov A, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study. Oncologist. 2023 10 03; 28(10):845-855. PMID: 37318349; PMCID: PMC10546823.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    10. Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, Garc?a-Pedrero J, Ca?adas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2023 10 02; 83(19):3284-3304. PMID: 37450351; PMCID: PMC10543960.
      Citations:    Fields:    Translation:HumansCells
    11. Sura GH, Tran K, Fu C, Du L, Marczyk M, Gould RE, Chen E, Tasto AM, Tinnirello AA, Symmans WF. Pre-analytical effects on whole transcriptome and targeted RNA sequencing analysis in cytology: The effects of prolonged time in storage of effusion specimens prior to preservation. Cytopathology. 2023 Nov; 34(6):551-561. PMID: 37712171; PMCID: PMC10592006.
      Citations:    Fields:    
    12. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422. PMID: 37547448; PMCID: PMC10399250.
    13. Clelland EN, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Symmans WF, Schwartz CJ, Chien AJ, Benz CC, Mukhtar RA. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes. Breast Cancer Res Treat. 2023 Nov; 202(2):367-375. PMID: 37500962; PMCID: PMC10505592.
      Citations:    Fields:    Translation:Humans
    14. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13). PMID: 37444385; PMCID: PMC10339918.
      Citations: 1     
    15. Yu H, Ding Q, ISPY-2 Locoregional Working Group, Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial. Ann Surg. 2023 09 01; 278(3):320-327. PMID: 37325931.
      Citations: 2     Fields:    Translation:Humans
    16. Speers CW, Barlow WE, Symmans WF. Reply to Y. Wang et al and Q. Sui et al. J Clin Oncol. 2023 Jul 20; 41(21):3763-3764. PMID: 37262407; PMCID: PMC10351949.
      Citations:    Fields:    
    17. Trevarton AJ, Chang JT, Symmans WF. Simple combination of multiple somatic variant callers to increase accuracy. Sci Rep. 2023 05 25; 13(1):8463. PMID: 37231022; PMCID: PMC10212967.
      Citations: 1     Fields:    Translation:Humans
    18. Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4. PMID: 37146605; PMCID: PMC10330514.
      Citations: 1     Fields:    Translation:Humans
    19. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469. PMID: 37061619.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    20. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401. PMID: 37043123.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    21. Rothschild HT, Clelland E, Patterson A, Molina-Vega J, Kaur M, Symmans WF, Schwartz CJ, Chien AJ, Mukhtar RA. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series. Breast Cancer Res Treat. 2023 Jun; 199(2):349-354. PMID: 37017812; PMCID: PMC10175465.
      Citations: 1     Fields:    Translation:Humans
    22. Osman AA, Arslan E, Bartels M, Michikawa C, Lindemann A, Tomczak K, Yu W, Sandulache V, Ma W, Shen L, Wang J, Singh AK, Frederick MJ, Spencer ND, Kovacs J, Heffernan T, Symmans WF, Rai K, Myers JN. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023 04 03; 29(7):1344-1359. PMID: 36689560; PMCID: PMC10068451.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    23. Liedtke C, Mazouni C, Hess KR, Andr? F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol. 2023 04 01; 41(10):1809-1815. PMID: 36989609.
      Citations:    Fields:    
    24. Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol. 2023 04 01; 41(10):1841-1848. PMID: 36649570; PMCID: PMC10082279.
      Citations: 1     Fields:    Translation:Humans
    25. Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Pusztai L, Hatzis C, Symmans WF. Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing. Cancer Cytopathol. 2023 05; 131(5):289-299. PMID: 36650408; PMCID: PMC10614161.
      Citations:    Fields:    Translation:HumansCells
    26. Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer. 2023 Jan 10; 9(1):2. PMID: 36627285; PMCID: PMC9831981.
    27. Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, Sanders ME, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Wheless A, Rezk S, Garrett AL, Parker JS, Foy KK, Shen H, Park BH, Krop I, Anders C, Gastier-Foster J, Rimawi MF, Nanda R, Lin NU, Isaacs C, Marcom PK, Storniolo AM, Couch FJ, Chandran U, Davis M, Silverstein J, Ropelewski A, Liu MC, Hilsenbeck SG, Norton L, Richardson AL, Symmans WF, Wolff AC, Davidson NE, Carey LA, Lee AV, Balko JM, Hoadley KA, Laird PW, Mardis ER, King TA, AURORA US Network, Perou CM. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023 01; 4(1):128-147. PMID: 36585450; PMCID: PMC9886551.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    28. Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ Breast Cancer. 2022 Dec 01; 8(1):128. PMID: 36456573; PMCID: PMC9715670.
      Citations: 1     
    29. Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 11 01; 157(11):1034-1041. PMID: 36069821; PMCID: PMC9453630.
    30. Sura GH, Tran K, Fu C, Du L, Marczyk M, Martinez Y, Tinnirello AA, Gould RE, Lau R, Symmans WF. Molecular testing opportunities on cytology effusion specimens: the pre-analytic effects of various body fluid cytology preparation methods on RNA extraction quality and targeted sequencing. J Am Soc Cytopathol. 2023 Jan-Feb; 12(1):10-19. PMID: 36270909; PMCID: PMC10644714.
      Citations:    Fields:    Translation:Humans
    31. Suman VJ, Du L, Hoskin T, Anurag M, Ma C, Bedrosian I, Hunt KK, Ellis MJ, Symmans WF. Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clin Cancer Res. 2022 08 02; 28(15):3287-3295. PMID: 35653124; PMCID: PMC9357183.
      Citations:    Fields:    
    32. Shinn EH, Busch BE, Jasemi N, Lyman CA, Toole JT, Richman SC, Symmans WF, Chavez-MacGregor M, Peterson SK, Broderick G. Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer. Front Psychol. 2022; 13:856813. PMID: 35903747; PMCID: PMC9315289.
    33. Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ, Copp? JP. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6. PMID: 35623341; PMCID: PMC9426306.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    34. Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L, I-SPY Consortium. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 08; 33(8):814-823. PMID: 35513244.
      Citations:    Fields:    
    35. Sahoo S, Krings G, Chen YY, Carter JM, Chen B, Guo H, Hibshoosh H, Reisenbichler E, Fan F, Wei S, Khazai L, Balassanian R, Klein ME, Shad S, Venters SJ, Borowsky AD, Symmans WF, Ocal IT. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy. Arch Pathol Lab Med. 2022 05 01; 147(5):591-603. PMID: 35976643.
    36. Mukhtar R, Symmans WF, Esserman LJ. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply. JAMA Oncol. 2022 04 01; 8(4):1. PMID: 35201273.
      Citations:    Fields:    Translation:Humans
    37. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5). PMID: 35267631; PMCID: PMC8909018.
    38. Yau C, Osdoit M, Esserman LJ, Symmans WF. Survivorship after neoadjuvant chemotherapy - Authors' reply. Lancet Oncol. 2022 03; 23(3):e96. PMID: 35240097.
      Citations:    Fields:    Translation:Humans
    39. Asad S, Kananen K, Mueller KR, Symmans WF, Wen Y, Perou CM, Blachly JS, Chen J, Vincent BG, Stover DG. Challenges and Gaps in Clinical Trial Genomic Data Management. JCO Clin Cancer Inform. 2022 03; 6:e2100193. PMID: 35404674; PMCID: PMC9012601.
      Citations:    Fields:    Translation:Humans
    40. Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo JP, Metzger O, Dunbar M, Symmans WF, Rastogi P, Sohn JH, Young R, Wright GS, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022 04; 33(4):384-394. PMID: 35093516.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    41. Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Fuqua SAW, And? S. Correction to: Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2022 Jan; 41(3):460. PMID: 34782721.
      Citations:    Fields:    
    42. Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF, La? M, Mart?n M, Del Monte-Mill?n M, L?pez-Tarruella S. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 01; 23(1):149-160. PMID: 34902335; PMCID: PMC9455620.
      Citations: 8     Fields:    Translation:Humans
    43. El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Sua LF, Liu SW, Lien HC, Kirtani P, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Spengler E, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Mehrotra R, Sarancone S, Rimm DL, Bartlett JMS, Viale G, Hida AI, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Demaria S, Loi S, International Immuno-Oncology Biomarker Working Group, Fujimoto L, Balancin M, Castaneda C, Acosta-Haab G, Willard-Gallo K, Richardet E, Ehinger A, Denkert C, Sotiriou C, Garcia-Rivello H, Michiels S. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 01; 7(1):150. PMID: 34853355; PMCID: PMC8636568.
      Citations: 9     
    44. Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer. 2021 Nov 11; 7(1):142. PMID: 34764307; PMCID: PMC8586340.
      Citations: 1     
    45. Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428. PMID: 34741023; PMCID: PMC8571284.
      Citations: 4     Fields:    Translation:Humans
    46. Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663. PMID: 34529000; PMCID: PMC8446908.
      Citations: 3     Fields:    Translation:Humans
    47. O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Carey LA, Krop I, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1?+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021 Dec; 17(34):4665-4676. PMID: 34636255; PMCID: PMC8600597.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    48. Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375. PMID: 34253579; PMCID: PMC8752638.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    49. Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Reply to T. Shimoi et al and Y. Shimanuki et al. J Clin Oncol. 2021 11 01; 39(31):3522-3524. PMID: 34554848; PMCID: PMC8547907.
      Citations: 2     Fields:    
    50. Bossuyt V, Lau R, Young B, Howe JG, Zhao F, Leyland-Jones B, Du L, Foli T, Hatzis C, Symmans WF. Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer. Clin Chem. 2021 09 01; 67(9):1240-1248. PMID: 34374711.
      Citations:    Fields:    Translation:Humans
    51. Symmans WF. Interpreting the Complex Landscape of Immune-Tumor Interface. Clin Cancer Res. 2021 10 15; 27(20):5446-5448. PMID: 34389608.
      Citations: 1     Fields:    Translation:Humans
    52. Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5. PMID: 34143979.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    53. Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021 08 10; 39(23):2539-2551. PMID: 34092112; PMCID: PMC8577688.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    54. Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Apr 01; 7(4):603-608. PMID: 33599688; PMCID: PMC7893540.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    55. Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Ann Oncol. 2021 05; 32(5):642-651. PMID: 33617937.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    56. Fu C, Marczyk M, Samuels M, Trevarton AJ, Qu J, Lau R, Du L, Pappas T, Gould RE, Pusztai L, Hatzis C, Symmans WF, Sinn BV. Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples. BMC Cancer. 2021 Feb 04; 21(1):114. PMID: 33541297; PMCID: PMC7860187.
      Citations:    Fields:    Translation:HumansCells
    57. Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021 05 01; 39(13):1485-1505. PMID: 33507815; PMCID: PMC8274745.
      Citations: 62     Fields:    Translation:Humans
    58. Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Fuqua SAW, And? S. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011. PMID: 33323970; PMCID: PMC8020875.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    59. Powell RT, Redwood A, Liu X, Guo L, Cai S, Zhou X, Tu Y, Zhang X, Qi Y, Jiang Y, Echeverria G, Feng N, Ma X, Giuliani V, Marszalek JR, Heffernan TP, Vellano CP, White JB, Stephan C, Davies PJ, Moulder S, Symmans WF, Chang JT, Piwnica-Worms H. Pharmacologic profiling of patient-derived xenograft models of primary treatment-na?ve triple-negative breast cancer. Sci Rep. 2020 10 21; 10(1):17899. PMID: 33087803; PMCID: PMC7578025.
      Citations: 3     Fields:    Translation:HumansAnimals
    60. Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs. 2021 04; 39(2):509-515. PMID: 32984932.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    61. I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362. PMID: 32701140; PMCID: PMC7378873.
      Citations: 22     Fields:    Translation:Humans
    62. Candelaria RP, Adrada BE, Hess K, Santiago L, Lane DL, Thompson AM, Moulder SL, Huang ML, Arribas EM, Rauch GM, Leung JWT, Symmans WF, Valero V, Ravenberg EE, White JB, Yang WT. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol. 2020 Sep; 130:109170. PMID: 32777736; PMCID: PMC7534548.
      Citations: 1     Fields:    Translation:Humans
    63. Lau R, Du L, Chen E, Fu C, Gould R, Marczyk M, Layman R, Bedrosian I, Valero V, Symmans WF, Sinn BV. Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. Clin Chem. 2020 07 01; 66(7):934-945. PMID: 32613237.
      Citations:    Fields:    Translation:Humans
    64. Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Yuan Y, AbdulJabbar K, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudecek J, Ciompi F, Moore DA, Singh R, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Badve SS, Khojasteh M, Symmans WF, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD, International Immuno-Oncology Biomarker Working Group, Denkert C, Wienert S, Roblin E, Balancin ML, Rojo F, Comerma L, Sotiriou C, Penault-Llorca F. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020; 6:16. PMID: 32411818; PMCID: PMC7217824.
      Citations: 27     
    65. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Rimm DL, Hewitt S, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Gruosso T, Fox SB, Araya JC, Floris G, Hudecek J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Castillo M, Curigliano G, Dieci MV, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Schnitt S, Lakhani SR, Braybrooke JP, Hanna MG, Bethmann D, Castaneda CA, Sharma A, Lien HC, Fineberg S, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Cooper L, Amgad M, Moore DA, Salgado R, International Immuno-Oncology Biomarker Working Group, Sotiriou C, Denkert C, Laenkholm AV, Bellolio E, Ehinger A, Wienert S, Andr? F, Penault-Llorca F, Vincent-Salomon A, Rojo F, Soler-Mons? MT, Willard-Gallo K, Thagaard J, Klaushen F. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020; 6:17. PMID: 32411819; PMCID: PMC7217863.
      Citations: 38     
    66. Hudecek J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Rimm DL, Hewitt SM, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM, International Immuno-Oncology Biomarker Working Group, Michiels S, Sotiriou C, Denkert C. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ Breast Cancer. 2020; 6:15. PMID: 32436923; PMCID: PMC7217941.
      Citations: 6     
    67. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684. PMID: 32053137; PMCID: PMC7058271.
      Citations: 126     Fields:    Translation:HumansCTClinical Trials
    68. Gonzalez-Ericsson PI, Stovgaard ES, Reisenbichler E, Kos Z, Carter JM, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Blackley EF, Demaria S, Leon-Ferre R, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M, International Immuno-Oncology Biomarker Working Group, Sua LF, Michiels S, Acosta-Haab G, Balancin M, Castaneda CA, Larsimont D, Sotiriou C, Denkert C, Gluz O. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020 04; 250(5):667-684. PMID: 32129476.
      Citations: 52     Fields:    Translation:HumansCells
    69. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020 05; 144(5):545-563. PMID: 31928354.
      Citations: 47     Fields:    Translation:Humans
    70. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020 04 20; 38(12):1346-1366. PMID: 31928404.
      Citations: 151     Fields:    Translation:Humans
    71. Weber KE, Fasching PA, Symmans WF, Karn T, Schem C, Stickeler E, Ataseven B, von Minckwitz G, Seliger B, Loibl S, Sinn BV, Schmitt WD, Blohmer JU, Taube ET, Klauschen F, Marm? F, Huober J, Denkert C. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res. 2019 12 11; 21(1):142. PMID: 31829264; PMCID: PMC6907189.
      Citations: 6     Fields:    Translation:HumansCells
    72. Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Gould RE, Pusztai L, Hatzis C, Symmans WF, Sinn BV. The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues. BMC Cancer. 2019 Dec 05; 19(1):1189. PMID: 31805884; PMCID: PMC6896723.
      Citations: 8     Fields:    Translation:Humans
    73. Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D, Campone M, Boileau JF. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019 09 01; 37(25):2206-2216. PMID: 31157583; PMCID: PMC6774816.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    74. Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, Shao J, Ma X, Harris A, Mundi P, Lau R, Ramamoorthy V, Wu Y, Alvarez MJ, Califano A, Moulder SL, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med. 2019 04 17; 11(488). PMID: 30996079; PMCID: PMC6541393.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    75. Shinn EH, Broderick G, Fellman B, Johnson A, Wieland E, Moulder S, Symmans WF. Simulating Time-Dependent Patterns of Nonadherence by Patients With Breast Cancer to Adjuvant Oral Endocrine Therapy. JCO Clin Cancer Inform. 2019 04; 3:1-9. PMID: 31002563; PMCID: PMC6873985.
      Citations: 5     Fields:    Translation:Humans
    76. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174. PMID: 31005169; PMCID: PMC6481318.
      Citations: 1     Fields:    Translation:Humans
    77. Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069. PMID: 32031889; PMCID: PMC7106976.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    78. Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Loi S, Michiels S. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019 02 01; 30(2):236-242. PMID: 30590484.
      Citations: 47     Fields:    Translation:HumansCells
    79. Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. NPJ Breast Cancer. 2019; 5:2. PMID: 30675512; PMCID: PMC6315027.
    80. Echeverria GV, Powell E, Seth S, Ge Z, Carugo A, Bristow C, Peoples M, Robinson F, Qiu H, Shao J, Jeter-Jones SL, Zhang X, Ramamoorthy V, Cai S, Wu W, Draetta G, Moulder SL, Symmans WF, Chang JT, Heffernan TP, Piwnica-Worms H. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun. 2018 11 29; 9(1):5079. PMID: 30498242; PMCID: PMC6265294.
      Citations: 51     Fields:    Translation:HumansAnimals
    81. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018 08 16; 71(4):606-620.e7. PMID: 30118680; PMCID: PMC6786495.
      Citations: 177     Fields:    Translation:HumansAnimalsCells
    82. Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton CJ, Bambhroliya A, Reuben JM, Van Laere SJ, Krishnamurthy S, Symmans WF, Brewster AM, Woodward WA. Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. Breast Cancer Res Treat. 2018 Sep; 171(2):283-293. PMID: 29858753.
      Citations: 9     Fields:    Translation:HumansCells
    83. Powell E, Shao J, Picon HM, Bristow C, Ge Z, Peoples M, Robinson F, Jeter-Jones SL, Schlosberg C, Grzeskowiak CL, Yang F, Wu Y, Wistuba I, Moulder SL, Symmans WF, Scott KL, Edwards JR, Liang H, Heffernan TP, Piwnica-Worms H. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. NPJ Breast Cancer. 2018; 4:9. PMID: 29736411; PMCID: PMC5928229.
      Citations: 16     
    84. Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018 07; 77:121-129. PMID: 29689244.
      Citations: 9     Fields:    Translation:HumansCells
    85. Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 04; 19(4):497-509. PMID: 29501363.
      Citations: 182     Fields:    Translation:HumansCTClinical Trials
    86. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777. PMID: 29385237; PMCID: PMC5931215.
      Citations: 89     Fields:    Translation:Humans
    87. Li J, Fu C, Speed TP, Wang W, Symmans WF. Accurate RNA Sequencing From Formalin-Fixed Cancer Tissue To Represent High-Quality Transcriptome From Frozen Tissue. JCO Precis Oncol. 2018; 2018. PMID: 29862382; PMCID: PMC5976456.
      Citations: 25     Fields:    
    88. Hurvitz SA, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D, Martin M, Campone M, Boileau JF, Beckmann MW. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 01; 19(1):115-126. PMID: 29175149.
      Citations: 110     Fields:    Translation:HumansCTClinical Trials
    89. Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, Byrd D, Hunt KK, Boughey JC. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Ann Surg. 2017 10; 266(4):667-676. PMID: 28657941; PMCID: PMC5755619.
      Citations: 15     Fields:    Translation:Humans
    90. Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT. Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. J Cancer. 2017; 8(6):1045-1052. PMID: 28529618; PMCID: PMC5436258.
      Citations: 6     
    91. Candelaria RP, Bassett RL, Symmans WF, Ramineni M, Moulder SL, Kuerer HM, Thompson AM, Yang WT. Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. Oncologist. 2017 04; 22(4):394-401. PMID: 28314842; PMCID: PMC5388386.
      Citations: 7     Fields:    Translation:Humans
    92. Sandberg LJ, Clemens MW, Symmans WF, Valero V, Caudle AS, Smith B, Kuerer HM, Hsu L, Kronowitz SJ. Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. Plast Reconstr Surg. 2017 Mar; 139(3):586e-596e. PMID: 28234813.
      Citations: 5     Fields:    Translation:Humans
    93. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060. PMID: 28135148; PMCID: PMC5455352.
      Citations: 161     Fields:    Translation:Humans
    94. Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Lifton RP, Symmans WF, Pusztai L, Hatzis C, Gyorffy B. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLoS Med. 2016 Dec; 13(12):e1002193. PMID: 27959926; PMCID: PMC5154510.
      Citations: 38     Fields:    Translation:Humans
    95. Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2017 Jun 15; 23(12):2991-3002. PMID: 27881578; PMCID: PMC5441976.
      Citations: 23     Fields:    Translation:HumansCells
    96. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346; PMCID: PMC5259558.
      Citations: 117     Fields:    Translation:HumansCTClinical Trials
    97. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347; PMCID: PMC5259561.
      Citations: 177     Fields:    Translation:HumansCTClinical Trials
    98. Bossuyt V, Symmans WF. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy. Ann Surg Oncol. 2016 10; 23(10):3153-61. PMID: 27380637.
      Citations: 7     Fields:    Translation:Humans
    99. Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016 Jul 01; 2(7):929-36. PMID: 26986538; PMCID: PMC5757376.
      Citations: 34     Fields:    Translation:Humans
    100. Vijay GV, Soundararajan R, Yu X, Symmans WF, Sphyris N, Mani SA, Pietil? M. FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition. Sci Rep. 2016 Apr 11; 6:23070. PMID: 27064522; PMCID: PMC4827390.
      Citations: 10     Fields:    Translation:HumansCells
    101. Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16. PMID: 26720612; PMCID: PMC4845895.
      Citations: 41     Fields:    Translation:Humans
    102. Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol. 2016 Apr; 29(4):330-46. PMID: 26916073.
      Citations: 16     Fields:    Translation:Humans
    103. Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):26-33. PMID: 26286912.
      Citations: 24     Fields:    Translation:Humans
    104. Pusztai L, Rouzier R, Symmans WF. CCR 20th Anniversary Commentary: Divide and Conquer-Breast Cancer Subtypes and Response to Therapy. Clin Cancer Res. 2015 Aug 15; 21(16):3575-7. PMID: 26275950.
      Citations: 3     Fields:    Translation:Humans
    105. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF, Residual Disease Characterization Working Group of the Breast International Group-North American Bre, Denkert C, MacGrogan G, Penault-Llorca F. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015 Sep; 28(9):1185-201. PMID: 26205180.
      Citations: 71     Fields:    Translation:Humans
    106. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015 Aug 20; 33(24):2695-704. PMID: 26195705; PMCID: PMC5478102.
      Citations: 104     Fields:    Translation:Humans
    107. Qi Y, Liu X, Liu CG, Wang B, Hess KR, Symmans WF, Shi W, Pusztai L. Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. PLoS One. 2015; 10(7):e0119230. PMID: 26136146; PMCID: PMC4489803.
      Citations: 8     Fields:    Translation:Humans
    108. Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Viale G, Cameron D, Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration, Denkert C, MacGrogan G, Penault-Llorca F. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015 Jul; 26(7):1280-91. PMID: 26019189; PMCID: PMC4804123.
      Citations: 57     Fields:    Translation:Humans
    109. Peintinger F, Sinn B, Hatzis C, Albarracin C, Downs-Kelly E, Morkowski J, Gould R, Symmans WF. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol. 2015 Jul; 28(7):913-20. PMID: 25932963; PMCID: PMC4830087.
      Citations: 31     Fields:    Translation:Humans
    110. Khan SS, Karn T, Symmans WF, Rody A, Holtrich U, Becker S, Pusztai L, Hatzis C, M?ller V. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. Breast Cancer Res Treat. 2015 Feb; 149(3):789-97. PMID: 25651779.
      Citations: 1     Fields:    Translation:Humans
    111. Symmans WF. Translational research in the National Cancer Institute's cooperative groups. Clin Adv Hematol Oncol. 2014 Nov; 12(11):785-7. PMID: 25674720.
      Citations: 1     Fields:    Translation:Humans
    112. Sheri A, Smith IE, Johnston SR, A'Hern R, Nerurkar A, Jones RL, Hills M, Detre S, Pinder SE, Symmans WF, Dowsett M. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol. 2015 Jan; 26(1):75-80. PMID: 25361988.
      Citations: 34     Fields:    Translation:Humans
    113. Salgado R, Demaria S, Pruneri G, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Viale G, Badve S, Adams S, Loi S, International TILs Working Group 2014, Denkert C, Sirtaine N, Klauschen F, Wienert S, Ignatiadis M, Sotiriou C, Willard-Gallo K. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb; 26(2):259-71. PMID: 25214542; PMCID: PMC6267863.
      Citations: 847     Fields:    Translation:HumansCells
    114. Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Gene signature-guided dasatinib therapy in metastatic breast cancer. Clin Cancer Res. 2014 Oct 15; 20(20):5265-71. PMID: 25172932.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    115. Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Fraser Symmans W, Lee MH, Yeung SC. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. J Natl Cancer Inst. 2014 Jul; 106(7). PMID: 24957076; PMCID: PMC4110474.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    116. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83. PMID: 24895461; PMCID: PMC4112583.
      Citations: 25     Fields:    Translation:HumansCells
    117. Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist. 2014 May; 19(5):453-8. PMID: 24710307; PMCID: PMC4012963.
      Citations: 28     Fields:    Translation:HumansCells
    118. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7. PMID: 24669015; PMCID: PMC4037860.
      Citations: 49     Fields:    Translation:HumansCellsCTClinical Trials
    119. Shi W, Balazs B, Jiang T, Symmans WF, Hatzis C, Pusztai L, Gy?rffy B. Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers. Breast Cancer Res Treat. 2014 Apr; 144(3):561-8. PMID: 24619174.
      Citations: 1     Fields:    Translation:HumansCells
    120. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11. PMID: 24562447; PMCID: PMC3999801.
      Citations: 62     Fields:    Translation:Humans
    121. Aktas B, Sun H, Yao H, Shi W, Hubbard R, Zhang Y, Jiang T, Ononye SN, Wali VB, Pusztai L, Symmans WF, Hatzis C. Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue. Mol Oncol. 2014 May; 8(3):717-27. PMID: 24602449; PMCID: PMC4048748.
      Citations: 13     Fields:    Translation:Humans
    122. Itoh M, Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Ohtani S, Higaki K, Fujiwara T, Doihara H, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat. 2014 Jan; 143(2):403-9. PMID: 24337596.
      Citations: 46     Fields:    Translation:Humans
    123. Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol. 2014 Feb; 25(2):358-65. PMID: 24299959; PMCID: PMC3905779.
      Citations: 47     Fields:    Translation:HumansCells
    124. Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2014 Feb; 23(2):316-23. PMID: 24296856; PMCID: PMC3946290.
      Citations: 13     Fields:    Translation:Humans
    125. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, Van Laere SJ, Hortobagyi GN, Ueno NT, Bertucci F. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 2013 Nov 25; 15(6):R112. PMID: 24274653; PMCID: PMC3978878.
      Citations: 27     Fields:    Translation:Humans
    126. Torikoshi Y, Gohda K, Davis ML, Symmans WF, Pusztai L, Kazansky A, Nakayama S, Yoshida T, Matsushima T, Hortobagyi GN, Ishihara H, Kim SJ, Noguchi S, Ueno NT. Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. J Cancer. 2013; 4(9):697-702. PMID: 24312139; PMCID: PMC3842438.
      Citations: 3     
    127. Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO, International Ki67 in Breast Cancer Working Group of the Breast International Group and North Americ, Polley MY, Penault-Llorca F. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013 Dec 18; 105(24):1897-906. PMID: 24203987; PMCID: PMC3888090.
      Citations: 193     Fields:    Translation:Humans
    128. Niikura N, Odisio BC, Tokuda Y, Symmans FW, Hortobagyi GN, Ueno NT. Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol. 2013 Dec; 10(12):711-9. PMID: 24145987.
      Citations: 3     Fields:    Translation:Humans
    129. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK, Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310(14):1455-61. PMID: 24101169; PMCID: PMC4075763.
      Citations: 280     Fields:    Translation:HumansCTClinical Trials
    130. Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Bottai G, Stampfer M, Turner NC, Symmans WF, Pusztai L, Bianchini G, Andr? F, Hortob?gyi GN. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist. 2013; 18(10):1063-73. PMID: 24072219; PMCID: PMC3805146.
      Citations: 40     Fields:    Translation:HumansCells
    131. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40. PMID: 23948975; PMCID: PMC3813597.
      Citations: 290     Fields:    Translation:Humans
    132. Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of ?III-tubulin expression as a predictive marker. Oncologist. 2013; 18(7):787-94. PMID: 23853246; PMCID: PMC3720631.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    133. Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res. 2013 May 15; 19(10):2723-33. PMID: 23549873; PMCID: PMC3655097.
      Citations: 77     Fields:    Translation:Humans
    134. Szekely B, Iwamoto T, Szasz AM, Qi Y, Matsuoka J, Symmans WF, Tokes AM, Kulka J, Swanton C, Pusztai L. A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. Breast Cancer Res Treat. 2013 Apr; 138(3):691-8. PMID: 23504136.
      Citations: 3     Fields:    Translation:Humans
    135. Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, Loi S, Swanton C, Azim HA, Andr? F. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol. 2013 Mar; 24(3):647-54. PMID: 23337633; PMCID: PMC6267878.
      Citations: 42     Fields:    Translation:Humans
    136. Kelly CM, Symmans WF, Andreopoulou E, Bianchini G. Breast cancer genomics: challenges in interpretation and application. Oncologist. 2013; 18(4):e11-2. PMID: 23633449; PMCID: PMC3639537.
      Citations: 1     Fields:    Translation:Humans
    137. Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly C, Schmidt S, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L, M?ller V. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res. 2013; 15(5):R86. PMID: 24060333; PMCID: PMC3978752.
      Citations: 19     Fields:    Translation:HumansCells
    138. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J. 2013 Jan-Feb; 19(1):10-7. PMID: 23337751; PMCID: PMC3568679.
      Citations: 29     Fields:    Translation:Humans
    139. Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat. 2013 Jan; 137(1):319-27. PMID: 23208590; PMCID: PMC3556743.
      Citations: 44     Fields:    Translation:Humans
    140. Shen K, Song N, Kim Y, Tian C, Rice SD, Gabrin MJ, Symmans WF, Pusztai L, Lee JK. A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy. PLoS One. 2012; 7(11):e49529. PMID: 23185353; PMCID: PMC3504014.
      Citations: 11     Fields:    Translation:HumansCells
    141. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
      Citations: 4     Fields:    Translation:Humans
    142. Shen K, Qi Y, Song N, Tian C, Rice SD, Gabrin MJ, Brower SL, Symmans WF, O'Shaughnessy JA, Holmes FA, Asmar L, Pusztai L. Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial. BMC Med Genomics. 2012 Nov 16; 5:51. PMID: 23158478; PMCID: PMC3536618.
      Citations: 15     Fields:    Translation:HumansCells
    143. Dixon JM, Wilson V, Verrill M, Symmans WF. HER2 testing in patients with breast cancer. BMJ. 2012 Jun 11; 344:e3958. PMID: 22689887.
      Citations:    Fields:    Translation:Humans
    144. McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012 May 04; 14(3):R72. PMID: 22559056; PMCID: PMC3446334.
      Citations: 59     Fields:    Translation:Humans
    145. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat. 2012 Jul; 134(1):333-43. PMID: 22538770; PMCID: PMC3885980.
      Citations: 53     Fields:    Translation:HumansCells
    146. Symmans WF. A perspective on genomic tests for breast cancer: the need for progress. Oncology (Williston Park). 2012 Apr; 26(4):364-5, 369. PMID: 22655530.
      Citations:    Fields:    Translation:Humans
    147. Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE, Zacksenhaus E. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERa- breast cancer. Proc Natl Acad Sci U S A. 2012 Apr 10; 109(15):5832-7. PMID: 22460789; PMCID: PMC3326451.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    148. Dutta B, Pusztai L, Qi Y, Lazar V, Bianchini G, Ueno N, Agarwal R, Wang B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, Andr? F, Bal?zsi G. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer. 2012 Mar 13; 106(6):1107-16. PMID: 22343619; PMCID: PMC3304402.
      Citations: 29     Fields:    Translation:HumansCells
    149. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 01; 30(7):729-34. PMID: 22291085.
      Citations: 92     Fields:    Translation:Humans
    150. Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res. 2012 Feb 15; 18(4):1109-19. PMID: 22235097; PMCID: PMC3288822.
      Citations: 30     Fields:    Translation:HumansCells
    151. Zhao C, Shi L, Tong W, Shaughnessy JD, Pusztai L, Deng Y, Symmans WF, Shi T, Oberthuer A. Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile. BMC Genomics. 2011 Dec 23; 12 Suppl 5:S3. PMID: 22369035; PMCID: PMC3287499.
      Citations: 2     Fields:    Translation:Humans
    152. Chang C, Wang J, Zhao C, Fostel J, Tong W, Bushel PR, Deng Y, Pusztai L, Symmans WF, Shi T. Maximizing biomarker discovery by minimizing gene signatures. BMC Genomics. 2011 Dec 23; 12 Suppl 5:S6. PMID: 22369133; PMCID: PMC3287502.
      Citations: 5     Fields:    Translation:Humans
    153. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012 May; 19(5):1508-16. PMID: 22193884.
      Citations: 151     Fields:    Translation:Humans
    154. Hess KR, Wei C, Qi Y, Iwamoto T, Symmans WF, Pusztai L. Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. BMC Bioinformatics. 2011 Dec 01; 12:463. PMID: 22132775; PMCID: PMC3245512.
      Citations: 5     Fields:    Translation:Humans
    155. Loi S, Symmans WF, Bartlett JM, Fumagalli D, Van't Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol. 2011 Nov; 12(12):1162-8. PMID: 21684810.
      Citations: 10     Fields:    Translation:Humans
    156. Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst. 2011 Dec 21; 103(24):1871-83. PMID: 22034635; PMCID: PMC3243675.
      Citations: 47     Fields:    Translation:Humans
    157. Iwamoto T, Lee JS, Bianchini G, Hubbard RE, Young E, Matsuoka J, Kim SB, Symmans WF, Hortobagyi GN, Pusztai L. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat. 2011 Nov; 130(1):155-64. PMID: 21833625.
      Citations: 9     Fields:    Translation:Humans
    158. Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kains B, Sotiriou C, Symmans WF, Pusztai L, Richardson AL, Szallasi Z, Brunak S. Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response. BMC Bioinformatics. 2011 Jul 28; 12:310. PMID: 21798043; PMCID: PMC3155975.
      Citations: 2     Fields:    Translation:Humans
    159. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics. 2011 Jul 08; 8(1):11. PMID: 21906370; PMCID: PMC3170272.
      Citations: 49     
    160. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Gomez H, Hubbard R, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF, Cotrina J, Chac?n JI. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81. PMID: 21558518; PMCID: PMC5638042.
      Citations: 305     Fields:    Translation:Humans
    161. Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L, Piccart-Gebhart M, Sotiriou C, Desmedt C, Lallemand F, D'Hondt V. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011 Apr 20; 29(12):1578-86. PMID: 21422418.
      Citations: 84     Fields:    Translation:Humans
    162. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9. PMID: 21209588; PMCID: PMC4331097.
      Citations: 13     Fields:    Translation:Humans
    163. Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, Pusztai L, de Th? H. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res. 2011 Apr 15; 17(8):2591-601. PMID: 21248301.
      Citations: 24     Fields:    Translation:Humans
    164. Symmans WF, Berruti A, Fox SB, Generali D. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. J Natl Cancer Inst Monogr. 2011; 2011(43):99-102. PMID: 22043052.
      Citations: 3     Fields:    Translation:Humans
    165. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011 Feb 02; 103(3):264-72. PMID: 21191116.
      Citations: 113     Fields:    Translation:HumansCells
    166. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb; 125(3):785-95. PMID: 21153052; PMCID: PMC4109066.
      Citations: 32     Fields:    Translation:HumansCells
    167. Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer. 2010 Nov 01; 116(21):4933-43. PMID: 20665494.
      Citations: 44     Fields:    Translation:Humans
    168. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res. 2010 Nov 01; 70(21):8852-62. PMID: 20959472.
      Citations: 21     Fields:    Translation:HumansCells
    169. Yi M, Kronowitz SJ, Meric-Bernstam F, Feig BW, Symmans WF, Lucci A, Ross MI, Babiera GV, Kuerer HM, Hunt KK. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. 2011 Mar 01; 117(5):916-24. PMID: 20945319; PMCID: PMC4371507.
      Citations: 23     Fields:    Translation:Humans
    170. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61. PMID: 20829329; PMCID: PMC4181852.
      Citations: 96     Fields:    Translation:Humans
    171. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010 Oct 01; 28(28):4316-23. PMID: 20805453.
      Citations: 102     Fields:    Translation:HumansCells
    172. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011 Jan 01; 117(1):39-47. PMID: 20740500; PMCID: PMC2997136.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    173. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010 Sep 20; 28(27):4111-9. PMID: 20697068; PMCID: PMC2953969.
      Citations: 126     Fields:    Translation:HumansCells
    174. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, Furlanello C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, Chen M, Cheng J, Cheng J, Chou J, Davison TS, Delorenzi M, Deng Y, Devanarayan V, Dix DJ, Dopazo J, Dorff KC, Elloumi F, Fan J, Fan S, Fan X, Fang H, Gonzaludo N, Hess KR, Hong H, Huan J, Irizarry RA, Judson R, Juraeva D, Lababidi S, Lambert CG, Li L, Li Y, Li Z, Lin SM, Liu G, Lobenhofer EK, Luo J, Luo W, McCall MN, Nikolsky Y, Pennello GA, Perkins RG, Philip R, Popovici V, Price ND, Qian F, Scherer A, Shi T, Shi W, Sung J, Thierry-Mieg D, Thierry-Mieg J, Thodima V, Trygg J, Vishnuvajjala L, Wang SJ, Wu J, Wu Y, Xie Q, Yousef WA, Zhang L, Zhang X, Zhong S, Zhou Y, Zhu S, Arasappan D, Bao W, Lucas AB, Berthold F, Brennan RJ, Buness A, Catalano JG, Chang C, Chen R, Cheng Y, Cui J, Czika W, Demichelis F, Deng X, Dosymbekov D, Eils R, Feng Y, Fostel J, Fulmer-Smentek S, Fuscoe JC, Gatto L, Ge W, Goldstein DR, Guo L, Halbert DN, Han J, Harris SC, Hatzis C, Herman D, Huang J, Jensen RV, Jiang R, Johnson CD, Jurman G, Kahlert Y, Khuder SA, Kohl M, Li J, Li M, Li QZ, Li S, Li Z, Liu J, Liu Y, Liu Z, Meng L, Madera M, Martinez-Murillo F, Medina I, Meehan J, Miclaus K, Moffitt RA, Montaner D, Mukherjee P, Mulligan GJ, Neville P, Nikolskaya T, Ning B, Page GP, Parker J, Parry RM, Peng X, Peterson RL, Phan JH, Quanz B, Ren Y, Riccadonna S, Roter AH, Samuelson FW, Schumacher MM, Shambaugh JD, Shi Q, Shippy R, Si S, Smalter A, Sotiriou C, Soukup M, Staedtler F, Steiner G, Stokes TH, Sun Q, Tan PY, Tang R, Tezak Z, Thorn B, Tsyganova M, Turpaz Y, Vega SC, Visintainer R, von Frese J, Wang C, Wang E, Wang J, Wang W, Westermann F, Willey JC, Woods M, Wu S, Xiao N, Xu J, Xu L, Yang L, Zeng X, Zhang J, Zhang L, Zhang M, Zhao C, Puri RK, Scherf U, Tong W, Wolfinger RD, MAQC Consortium, Oberthuer A. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010 Aug; 28(8):827-38. PMID: 20676074; PMCID: PMC3315840.
      Citations: 355     Fields:    Translation:HumansAnimals
    175. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A. 2010 Jun 01; 107(22):10208-13. PMID: 20479250; PMCID: PMC2890442.
      Citations: 173     Fields:    Translation:HumansCells
    176. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther. 2010 May; 9(5):1120-7. PMID: 20423993.
      Citations: 10     Fields:    Translation:HumansCells
    177. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Apr 10; 28(11):1821-8. PMID: 20231683; PMCID: PMC2860366.
      Citations: 57     Fields:    Translation:Humans
    178. Desmedt C, Mazouni C, Giacchetti S, Turpin E, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, Lehmann-Che J, Andr? F, Espi? M, Plassa LF, de Th? H. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist. 2010; 15(3):246-52. PMID: 20228131; PMCID: PMC3227956.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    179. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol. 2010 Apr; 11(4):358-65. PMID: 20189874.
      Citations: 55     Fields:    Translation:Humans
    180. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163. PMID: 20121597.
      Citations: 1     Fields:    Translation:Humans
    181. Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, Baggerly K, Rouzier R, Pusztai L. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2010 Jan 15; 16(2):711-8. PMID: 20068086; PMCID: PMC2807997.
      Citations: 39     Fields:    Translation:Humans
    182. Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L, Popovici V. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010; 12(1):R5. PMID: 20064235; PMCID: PMC2880423.
      Citations: 98     Fields:    Translation:Humans
    183. Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat. 2010 Oct; 123(3):747-55. PMID: 20024612.
      Citations: 14     Fields:    Translation:HumansCells
    184. Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009 Nov 15; 69(22):8579-84. PMID: 19887608.
      Citations: 73     Fields:    Translation:HumansAnimalsCells
    185. Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F, Hortobagyi GN, Wolmark N, Symmans WF. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol. 2009 Sep 10; 27(26):4287-92. PMID: 19667268; PMCID: PMC2744271.
      Citations: 37     Fields:    Translation:Humans
    186. Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR. The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform. 2009 Aug 05; 7:199-216. PMID: 19718451; PMCID: PMC2730180.
      Citations: 61     
    187. Gong Y, Sweet W, Duh YJ, Greenfield L, Tarco E, Trivedi S, Symmans WF, Isola J, Sneige N. Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. Am J Clin Pathol. 2009 Aug; 132(2):228-36. PMID: 19605817.
      Citations: 5     Fields:    Translation:HumansCells
    188. Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K, Baggerly KA, Coombes KR, Pusztai L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat. 2010 Jun; 121(2):301-9. PMID: 19603265.
      Citations: 23     Fields:    Translation:HumansCells
    189. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009 Dec; 20(12):1953-8. PMID: 19596702; PMCID: PMC2791352.
      Citations: 117     Fields:    Translation:Humans
    190. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol. 2009 Jul 01; 27(19):3185-91. PMID: 19364972; PMCID: PMC2716940.
      Citations: 67     Fields:    Translation:Humans
    191. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009 Apr; 14(4):320-68. PMID: 19346299.
      Citations: 397     Fields:    Translation:HumansCells
    192. Gong Y, Sweet W, Duh YJ, Greenfield L, Fang Y, Zhao J, Tarco E, Symmans WF, Isola J, Sneige N. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol. 2009 Apr; 131(4):490-7. PMID: 19289584.
      Citations: 12     Fields:    Translation:Humans
    193. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res. 2009 Feb 15; 15(4):1326-34. PMID: 19228734; PMCID: PMC2663973.
      Citations: 37     Fields:    Translation:HumansCells
    194. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009 Jan 15; 15(2):441-51. PMID: 19147748.
      Citations: 135     Fields:    Translation:HumansCells
    195. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88. PMID: 19064970.
      Citations: 56     Fields:    Translation:HumansAnimals
    196. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7909-16. PMID: 19047121; PMCID: PMC4375958.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    197. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Mills GB, Hennessy BT, Bernards R. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008 Aug 01; 68(15):6084-91. PMID: 18676830; PMCID: PMC2680495.
      Citations: 498     Fields:    Translation:Humans
    198. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol. 2008 Dec; 19(12):2020-5. PMID: 18667396; PMCID: PMC2733116.
      Citations: 13     Fields:    Translation:Humans
    199. Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. J Clin Oncol. 2008 Oct 01; 26(28):4679-83. PMID: 18662965.
      Citations: 12     Fields:    Translation:Humans
    200. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortob?gyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008 May; 13(5):477-93. PMID: 18515733.
      Citations: 71     Fields:    Translation:HumansPHPublic Health
    201. Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res. 2008; 10(2):R37. PMID: 18445275; PMCID: PMC2397539.
      Citations: 27     Fields:    Translation:HumansCells
    202. Mathieu MC, Mazouni C, Liedtke C, Corley L, Geha S, Spielmann M, Drusche F, Symmans WF, Zoubir M, Bouaziz J, Delaloge S, Andre F. Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Ann Oncol. 2008 Aug; 19(8):1402-1406. PMID: 18436523.
      Citations: 8     Fields:    Translation:HumansCells
    203. Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg. 2008 Apr; 95(4):433-7. PMID: 18161887.
      Citations: 6     Fields:    Translation:Humans
    204. Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am J Surg Pathol. 2008 Apr; 32(4):544-52. PMID: 18300793.
      Citations: 20     Fields:    Translation:Humans
    205. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res. 2008; 10(2):R27. PMID: 18371219; PMCID: PMC2397526.
      Citations: 24     Fields:    Translation:Humans
    206. Symmans WF, Hortobagyi GN. Fingerprinting lymph node metastases. Ann Surg Oncol. 2008 May; 15(5):1275-6. PMID: 18340490; PMCID: PMC2277447.
      Citations:    Fields:    Translation:Humans
    207. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9. PMID: 18258991.
      Citations: 123     Fields:    Translation:Humans
    208. Liedtke C, Mazouni C, Hess KR, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L, Andr? F. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1275-81. PMID: 18250347.
      Citations: 1030     Fields:    Translation:Humans
    209. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Gonzalez-Angulo AM, Hortob?gyi GN. Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist. 2008 Jan; 13(1):6-15. PMID: 18245008.
      Citations: 7     Fields:    Translation:Humans
    210. Diaz LK, Cryns VL, Symmans WF, Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol. 2007 Nov; 14(6):419-30. PMID: 18049131.
      Citations: 41     Fields:    Translation:Humans
    211. Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF, Perkins GH, Buchholz TA, Babiera GV, Kuerer HM, Bedrosian I, Akins JS, Hunt KK. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007 Oct; 194(4):527-31. PMID: 17826073.
      Citations: 32     Fields:    Translation:Humans
    212. Gong Y, Symmans WF, Pusztai L. Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. Pharmacogenomics. 2007 Oct; 8(10):1359-68. PMID: 17979510.
      Citations: 2     Fields:    Translation:Humans
    213. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer. 2007 Sep 15; 110(6):1195-200. PMID: 17647266.
      Citations: 12     Fields:    Translation:Humans
    214. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 01; 25(28):4414-22. PMID: 17785706.
      Citations: 450     Fields:    Translation:Humans
    215. Williams SA, Ehlers RA, Hunt KK, Yi M, Kuerer HM, Singletary SE, Ross MI, Feig BW, Symmans WF, Meric-Bernstam F. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer. 2007 Aug 15; 110(4):731-7. PMID: 17582626.
      Citations: 46     Fields:    Translation:Humans
    216. Peintinger F, Anderson K, Mazouni C, Kuerer HM, Hatzis C, Lin F, Hortobagyi GN, Symmans WF, Pusztai L. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. Clin Cancer Res. 2007 Jul 15; 13(14):4078-82. PMID: 17634532.
      Citations: 8     Fields:    Translation:Humans
    217. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007 Jul 01; 25(19):2650-5. PMID: 17602071.
      Citations: 88     Fields:    Translation:Humans
    218. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res. 2007 May 15; 13(10):2831-5. PMID: 17504980.
      Citations: 21     Fields:    Translation:Humans
    219. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat. 2008 Mar; 108(2):183-90. PMID: 17468948.
      Citations: 39     Fields:    Translation:Humans
    220. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res. 2007 Apr 01; 13(7):2061-7. PMID: 17404087.
      Citations: 41     Fields:    Translation:Humans
    221. Symmans WF. A pathologist's perspective on emerging genomic tests for breast cancer. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S4-9. PMID: 17512433.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    222. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007 Mar; 8(3):203-11. PMID: 17329190.
      Citations: 73     Fields:    Translation:Humans
    223. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007 May; 18(5):874-80. PMID: 17293601.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    224. Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J. 2007 Jan-Feb; 13(1):72-5. PMID: 17214797.
      Citations: 7     Fields:    Translation:Humans
    225. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 01; 13(1):228-33. PMID: 17200359.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    226. Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res. 2007; 9(6):R87. PMID: 18086299; PMCID: PMC2246190.
      Citations: 14     Fields:    Translation:HumansCells
    227. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Personalized medicine for breast cancer: moving forward and going back. Per Med. 2006 Nov; 3(4):363-370. PMID: 29788594.
      Citations:    Fields:    
    228. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006 Nov; 13(11):1443-9. PMID: 17028770.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    229. Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54. PMID: 16862596.
      Citations: 10     Fields:    Translation:Humans
    230. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist. 2006 Sep; 11(8):868-77. PMID: 16951390.
      Citations: 64     Fields:    Translation:Humans
    231. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Hortobagyi GN, Pusztai L, G?mez HL. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44. PMID: 16896004.
      Citations: 264     Fields:    Translation:Humans
    232. Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT, Esteva FJ. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol Cancer Ther. 2006 Jun; 5(6):1593-601. PMID: 16818519.
      Citations: 20     Fields:    Translation:HumansCells
    233. Kawase K, Gayed IW, Hunt KK, Kuerer HM, Akins J, Yi M, Grimes L, Babiera GV, Ross MI, Feig BW, Ames FC, Singletary SE, Buchholz TA, Symmans WF, Meric-Bernstam F. Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg. 2006 Jul; 203(1):64-72. PMID: 16798488.
      Citations: 6     Fields:    Translation:Humans
    234. Symmans WF. Genomic testing for sensitivity of breast cancer to hormonal therapy. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1954-5. PMID: 16609001.
      Citations:    Fields:    Translation:Humans
    235. Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y, Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res. 2006 Mar 15; 12(6):1721-7. PMID: 16551855.
      Citations: 8     Fields:    Translation:Humans
    236. Ji Y, Coombes K, Zhang J, Wen S, Mitchell J, Pusztai L, Symmans WF, Wang J. RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms. Appl Bioinformatics. 2006; 5(2):89-98. PMID: 16722773.
      Citations: 3     Fields:    Translation:HumansCells
    237. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50. PMID: 16333852.
      Citations: 4     Fields:    Translation:Humans
    238. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics and clinical biomarkers in drug discovery and development. Am J Clin Pathol. 2005 Dec; 124 Suppl:S29-41. PMID: 16468416.
      Citations: 10     Fields:    Translation:Humans
    239. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer. 2005 Dec; 12(4):1059-69. PMID: 16322343.
      Citations: 21     Fields:    Translation:Humans
    240. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9. PMID: 16293864.
      Citations: 82     Fields:    Translation:Humans
    241. Tari AM, Simeone AM, Li YJ, Gutierrez-Puente Y, Lai S, Symmans WF. Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab Invest. 2005 Nov; 85(11):1357-67. PMID: 16127422.
      Citations: 9     Fields:    Translation:HumansCells
    242. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005 Oct 10; 23(29):7265-77. PMID: 16145055.
      Citations: 154     Fields:    Translation:Humans
    243. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16):5678-85. PMID: 16115903.
      Citations: 602     Fields:    Translation:Humans
    244. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91. PMID: 15986399.
      Citations: 81     Fields:    Translation:HumansCTClinical Trials
    245. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92. PMID: 16087943.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    246. Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell S, Linette G, Hortobagyi GN, Fraser Symmans W, Pusztai L. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn. 2005 Aug; 7(3):357-67. PMID: 16049308; PMCID: PMC1867535.
      Citations: 16     Fields:    Translation:Humans
    247. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005 Jun 07; 102(23):8315-20. PMID: 15914550; PMCID: PMC1149405.
      Citations: 129     Fields:    Translation:HumansCells
    248. Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, Ames FC, Kuerer HM. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005 Apr; 200(4):516-26. PMID: 15804465.
      Citations: 64     Fields:    Translation:Humans
    249. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Breast cancer biomarkers. Adv Clin Chem. 2005; 40:99-125. PMID: 16355921.
      Citations: 9     Fields:    Translation:Humans
    250. Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer. 2005; 12(2):73-85. PMID: 15858436.
      Citations: 5     Fields:    Translation:Humans
    251. Pusztai L, Rouzier R, Wagner P, Symmans WF. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Drug Resist Updat. 2004 Dec; 7(6):325-31. PMID: 15790543.
      Citations: 3     Fields:    Translation:Humans
    252. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapies for cancer 2004. Am J Clin Pathol. 2004 Oct; 122(4):598-609. PMID: 15487459.
      Citations: 43     Fields:    Translation:Humans
    253. Rajan R, Esteva FJ, Symmans WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response. Clin Breast Cancer. 2004 Aug; 5(3):235-8. PMID: 15335458.
      Citations: 10     Fields:    Translation:Humans
    254. Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics. Adv Anat Pathol. 2004 Jul; 11(4):211-20. PMID: 15220824.
      Citations: 4     Fields:    Translation:Humans
    255. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93. PMID: 15136595.
      Citations: 116     Fields:    Translation:Humans
    256. Pusztai L, Gregory BW, Baggerly KA, Peng B, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer. 2004 May 01; 100(9):1814-22. PMID: 15112261.
      Citations: 23     Fields:    Translation:Humans
    257. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer. 2004 Apr 01; 100(7):1365-73. PMID: 15042669.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    258. Hao X, Sun B, Hu L, Dunmire V, Feng Y, Zhang SW, Wang H, Wu C, Wang H, Fuller GN, Symmans WF, Shmulevich I, Zhang W, L?hdesm?ki H. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer. 2004 Mar 15; 100(6):1110-22. PMID: 15022276.
      Citations: 85     Fields:    Translation:Humans
    259. Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn. 2004 Mar; 4(2):169-88. PMID: 14995904.
      Citations: 15     Fields:    Translation:Humans
    260. Gong Y, Symmans WF, Krishnamurthy S, Patel S, Sneige N. Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma. Cancer. 2004 Feb 25; 102(1):34-40. PMID: 14968416.
      Citations: 14     Fields:    Translation:Humans
    261. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004 Apr; 3(4):379-98. PMID: 14762215.
      Citations: 80     Fields:    Translation:Humans
    262. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN. HER-2/neu testing in breast cancer. Am J Clin Pathol. 2003 Dec; 120 Suppl:S53-71. PMID: 15298144.
      Citations: 14     Fields:    Translation:Humans
    263. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 15; 21(18):3454-61. PMID: 12972520.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    264. Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn. 2003 Sep; 3(5):573-85. PMID: 14510178.
      Citations: 28     Fields:    Translation:HumansPHPublic Health
    265. Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R, Dai JL. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 2003 Aug 01; 63(15):4724-30. PMID: 12907655.
      Citations: 60     Fields:    Translation:HumansCells
    266. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15. PMID: 12855612.
      Citations: 43     Fields:    Translation:HumansCells
    267. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71. PMID: 12784330.
      Citations: 48     Fields:    Translation:Humans
    268. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer. 2003 Apr 01; 97(7):1758-65. PMID: 12655533.
      Citations: 18     Fields:    Translation:Humans
    269. Diaz LK, Hunt K, Ames F, Meric F, Kuerer H, Babiera G, Ross M, Singletary E, Middleton LP, Symmans WF, Krishnamurthy S, Sahin A, Sneige N, Gilcrease MZ. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9. PMID: 12604895.
      Citations: 5     Fields:    Translation:Humans
    270. Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. Cancer Genet Cytogenet. 2003 Mar; 141(2):148-53. PMID: 12606133.
      Citations: 4     Fields:    Translation:Humans
    271. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003; 8(4):307-25. PMID: 12897328.
      Citations: 157     Fields:    Translation:Humans
    272. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003 Jan-Feb; 9(1):33-41. PMID: 12602766.
      Citations: 43     Fields:    Translation:Humans
    273. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002 Nov-Dec; 8(6):461-8. PMID: 12500855.
      Citations: 26     Fields:    Translation:Humans
    274. Lee A, Krishnamurthy S, Sahin A, Symmans WF, Hunt K, Sneige N. Intraoperative touch imprint of sentinel lymph nodes in breast carcinoma patients. Cancer. 2002 Aug 25; 96(4):225-31. PMID: 12209664.
      Citations: 12     Fields:    Translation:Humans
    275. Kronowitz SJ, Chang DW, Robb GL, Hunt KK, Ames FC, Ross MI, Singletary SE, Symmans WF, Kroll SS, Kuerer HM. Implications of axillary sentinel lymph node biopsy in immediate autologous breast reconstruction. Plast Reconstr Surg. 2002 May; 109(6):1888-96. PMID: 11994589.
      Citations: 4     Fields:    Translation:Humans
    276. Symmans FW. Breast cancer response to paclitaxel in vivo. Drug Resist Updat. 2001 Oct; 4(5):297-302. PMID: 11991683.
      Citations: 6     Fields:    Translation:Humans
    277. Symmans WF, Cangiarella JF, Gottlieb S, Newstead GM, Waisman J. What is the role of cytopathologists in stereotaxic needle biopsy diagnosis of nonpalpable mammographic abnormalities? Diagn Cytopathol. 2001 Apr; 24(4):260-70. PMID: 11285624.
      Citations:    Fields:    Translation:Humans
    278. Chhieng DC, Cangiarella JF, Symmans WF, Cohen JM. Fine-needle aspiration cytology of Hodgkin disease: a study of 89 cases with emphasis on false-negative cases. Cancer. 2001 Feb 25; 93(1):52-9. PMID: 11241266.
      Citations: 10     Fields:    Translation:Humans
    279. Cangiarella J, Waisman J, Cohen JM, Chhieng D, Symmans WF, Axelrod D, Gross J. Radial sclerosing lesion: correlation between mammotome core biopsy and surgical excision. Breast J. 2001 Jan-Feb; 7(1):66-7. PMID: 11348419.
      Citations:    Fields:    Translation:Humans
    280. Cangiarella J, Waisman J, Symmans WF, Gross J, Cohen JM, Wu H, Axelrod D. Mammotome core biopsy for mammary microcalcification: analysis of 160 biopsies from 142 women with surgical and radiologic followup. Cancer. 2001 Jan 01; 91(1):173-7. PMID: 11148574.
      Citations: 15     Fields:    Translation:Humans
    281. Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res. 2000 Dec; 6(12):4610-7. PMID: 11156210.
      Citations: 41     Fields:    Translation:Humans
    282. Cangiarella JF, Waisman J, Weg N, Tata M, Gross J, Symmans WF. The Use of Stereotaxic Core Biopsy and Stereotaxic Aspiration Biopsy as Diagnostic Tools in the Evaluation of Mammary Calcification. Breast J. 2000 Nov; 6(6):366-372. PMID: 11348394.
      Citations:    Fields:    
    283. Chhieng DC, Yee H, Cangiarella JF, Symmans WF, Cohen JM. Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells and carcinoma cells in pelvic washings. Cancer. 2000 Oct 25; 90(5):299-306. PMID: 11038427.
      Citations: 5     Fields:    Translation:HumansCells
    284. Cangiarella J, Gross J, Symmans WF, Waisman J, Petersen B, D'Angelo D, Singer C, Axelrod D. The incidence of positive margins with breast conserving therapy following mammotome biopsy for microcalcification. J Surg Oncol. 2000 Aug; 74(4):263-6. PMID: 10962457.
      Citations: 4     Fields:    Translation:Humans
    285. Cangiarella J, Symmans WF, Shapiro RL, Roses DF, Cohen JM, Chhieng D, Harris MN, Waisman J. Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. Cancer. 2000 Jun 25; 90(3):162-6. PMID: 10896329.
      Citations: 5     Fields:    Translation:Humans
    286. Chhieng DC, Fernandez G, Cangiarella JF, Cohen JM, Waisman J, Harris MN, Roses DF, Shapiro RL, Symmans WF. Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspiration. Cancer. 2000 Apr 25; 90(2):96-101. PMID: 10794158.
      Citations: 1     Fields:    Translation:Humans
    287. Symmans WF, Cangiarella JF, Symmans PJ, Cohen JM, Yee HT, Bennett G, Amorosi EL, Waisman J. Apoptotic index from fine needle aspiration cytology as a criterion to predict histologic grade of non-Hodgkin's lymphoma. Acta Cytol. 2000 Mar-Apr; 44(2):194-204. PMID: 10740606.
      Citations: 1     Fields:    Translation:Humans
    288. Moreira AL, Haslett PA, Symmans WF. Propionibacterium acnes as the cause of endocarditis in a liver transplant recipient. Clin Infect Dis. 2000 Jan; 30(1):224-6. PMID: 10619770.
      Citations: 6     Fields:    Translation:HumansCells
    289. Cangiarella J, Waisman J, Cohen JM, Chhieng D, Symmans WF, Goldenberg A. Plasmacytoma of the breast. A report of two cases diagnosed by aspiration biopsy. Acta Cytol. 2000 Jan-Feb; 44(1):91-4. PMID: 10667168.
      Citations: 4     Fields:    Translation:Humans
    290. Zeng Z, Melamed J, Symmans PJ, Cangiarella JF, Shapiro RL, Peralta H, Symmans WF. Benign proliferative nipple duct lesions frequently contain CAM 5.2 and anti-cytokeratin 7 immunoreactive cells in the overlying epidermis. Am J Surg Pathol. 1999 Nov; 23(11):1349-55. PMID: 10555003.
      Citations: 2     Fields:    Translation:Humans
    291. Formenti SC, Symmans WF, Volm M, Skinner K, Cohen D, Spicer D, Danenberg PV. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):34-42. PMID: 10210538.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    292. Symmans WF, Weg N, Gross J, Cangiarella JF, Tata M, Mazzo JA, Waisman J. A prospective comparison of stereotaxic fine-needle aspiration versus stereotaxic core needle biopsy for the diagnosis of mammographic abnormalities. Cancer. 1999 Mar 01; 85(5):1119-32. PMID: 10091797.
      Citations: 3     Fields:    Translation:Humans
    293. Mangues R, Corral T, Lu S, Symmans WF, Liu L, Pellicer A. NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity. Oncogene. 1998 Oct 01; 17(13):1705-16. PMID: 9796699.
      Citations: 5     Fields:    Translation:AnimalsCells
    294. Cangiarella J, Mercado CL, Symmans WF, Newstead GM, Toth HK, Waisman J. Stereotaxic aspiration biopsy in the evaluation of mammographically detected clustered microcalcification. Cancer. 1998 Aug 25; 84(4):226-30. PMID: 9723597.
      Citations:    Fields:    Translation:Humans
    295. Illei PB, Feiner HD, Symmans WF, Mitnick JS, Roses DF, Perle MA. Numerical abnormalities of chromosomes 7, 18, and x in precancerous breast disease defined by fluorescent in situ hybridization. Breast J. 1998 Jul; 4(4):252-7. PMID: 21223444.
      Citations:    Fields:    
    296. Cangiarella J, Symmans WF, Cohen JM, Goldenberg A, Shapiro RL, Waisman J. Malignant melanoma metastatic to the breast: a report of seven cases diagnosed by fine-needle aspiration cytology. Cancer. 1998 Jun 25; 84(3):160-2. PMID: 9678730.
      Citations: 14     Fields:    Translation:Humans
    297. Mangues R, Corral T, Kohl NE, Symmans WF, Lu S, Malumbres M, Gibbs JB, Oliff A, Pellicer A. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 1998 Mar 15; 58(6):1253-9. PMID: 9515813.
      Citations: 18     Fields:    Translation:AnimalsCells
    298. Stokes MB, Kumar A, Symmans WF, Scholes JV, Melamed J. Pancreatic endocrine tumor with signet ring cell features: a case report with novel ultrastructural observations. Ultrastruct Pathol. 1998 Mar-Apr; 22(2):147-52. PMID: 9615384.
      Citations: 2     Fields:    Translation:Humans
    299. Cangiarella J, Weg N, Symmans WF, Waisman J. Aspiration cytology of signet-ring cell lymphoma. A case report. Acta Cytol. 1997 Nov-Dec; 41(6):1828-32. PMID: 9390152.
      Citations:    Fields:    Translation:Humans
    300. Mangues R, Symmans WF, Lu S, Schwartz S, Pellicer A. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene. 1996 Sep 05; 13(5):1053-63. PMID: 8806695.
      Citations: 11     Fields:    Translation:AnimalsCells
    301. Zhau HY, Zhou J, Symmans WF, Chen BQ, Chang SM, Sikes RA, Chung LW. Transfected neu oncogene induces human prostate cancer metastasis. Prostate. 1996 Feb; 28(2):73-83. PMID: 8604395.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    302. Waisman J, Symmans F, Ljung BM. Epithelial displacement. Am J Surg Pathol. 1995 Sep; 19(9):1092-4. PMID: 7661284.
      Citations:    Fields:    Translation:Humans
    303. Symmans WF, Katz RL, Dalton H, Romaguera JE, Cabanillas F, Ordo?ez NG. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytol. 1995 Jul-Aug; 39(4):673-82. PMID: 7631541.
      Citations: 4     Fields:    Translation:Humans
    304. Symmans WF, Marboe CC. Cardiac allograft pathology-A comment on the problem of chronic rejection. Cardiovasc Pathol. 1995 Jul-Sep; 4(3):223. PMID: 25851014.
      Citations:    Fields:    
    305. Symmans WF, Liu J, Knowles DM, Inghirami G. Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol. 1995 Feb; 26(2):210-6. PMID: 7860051.
      Citations: 24     Fields:    Translation:HumansCells
    306. Avellino AM, Hair LS, Symmans WF, Gold AP, Carmel P, Powers JM. Meningeal meningiomatosis in a child: case report. Clin Neuropathol. 1994 Mar-Apr; 13(2):82-7. PMID: 8205731.
      Citations: 2     Fields:    Translation:Humans
    307. Dodd LG, Evans DB, Symmans F, Katz RL. Fine-needle aspiration of pancreatic extramedullary plasmacytoma: possible confusion with islet cell tumor. Diagn Cytopathol. 1994; 10(4):371-4; discussion 374-5. PMID: 7924813.
      Citations: 3     Fields:    Translation:Humans
    308. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993 Aug; 143(2):390-400. PMID: 7688182; PMCID: PMC1887010.
      Citations: 113     Fields:    Translation:Humans
    309. Symmans F, Mechanic L, MacConnell P, DaSilva K, Stricker B, Nuovo GJ. Correlation of cervical cytology and human papillomavirus DNA detection in postmenopausal women. Int J Gynecol Pathol. 1992 Jul; 11(3):204-9. PMID: 1328078.
      Citations: 1     Fields:    Translation:HumansCells
    310. Hair LS, Symmans F, Powers JM, Carmel P. Immunohistochemistry and proliferative activity in Lhermitte-Duclos disease. Acta Neuropathol. 1992; 84(5):570-3. PMID: 1462769.
      Citations: 5     Fields:    Translation:HumansCells
    311. Despommier D, Symmans WF, Dell R. Changes in nurse cell nuclei during synchronous infection with Trichinella spiralis. J Parasitol. 1991 Apr; 77(2):290-5. PMID: 2010862.
      Citations: 5     Fields:    Translation:AnimalsCells
    312. Koulos J, Symmans F, Chumas J, Nuovo G. Human papillomavirus detection in adenocarcinoma of the anus. Mod Pathol. 1991 Jan; 4(1):58-61. PMID: 1850518.
      Citations: 10     Fields:    Translation:HumansCells
    313. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology. 26:1280-1291.
    314. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Modern Pathology.
    315. Uncertainty estimation with a finite dataset in the assessment of classification models. Computational Statistics and Data Analysis. 56:1016-1027.
    316. Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. Journal of Cancer. 4:697-702.
    317. FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition. Scientific Reports. 6.
    318. Reproducibility of variant calls in replicate next generation sequencing experiments. PLoS One. 10.
    319. Molecular profiling using breast cancer subtype to plan for breast reconstruction. Plastic and Reconstructive Surgery.
    320. A perspective on genomic tests for breast cancer. Oncology. 26.
    321. Decrease in bcl-2 expression shortly after neoadjuvant chemotherapy predicts primary breast cancer response to treatment. Breast Cancer Research and Treatment. 69:244.
    322. Cardiac allograft pathology. Cardiovascular Pathology. 3:249-256.
    323. Predictors of Chemosensitivity in Triple Negative Breast Cancer. PLoS Medicine. 13.
    324. Characterization of DNA variants in the human kinome in breast cancer. Scientific Reports. 5.
    325. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple-negative breast cancer. Clinical Cancer Research. 22:26-33.
    326. Personalized medicine for breast cancer. Personalized Medicine. 3:363-370.
    327. Molecular Pathology Assays for Breast Cancer. 145-168.
    328. In reply. Journal of Clinical Oncology. 26:3095.
    329. Molecular Pathology and Transcriptional Profiling in Early Drug Development. 47-84.
    330. Clinical relevance of HER-2 amplification and overexpression in human cancers. References en Gynecologie Obstetrique. 7:267-276.
    331. The use of stereotaxic core biopsy and stereotaxic aspiration biopsy as diagnostic tools in the evaluation of mammary calcification. Breast Journal. 6:366-372.
    332. The neoadjuvant model is still the future for drug development in breast cancer. Clinical Cancer Research. 21:2911-2915.
    333. Comparative studies of prostate cancers among United States, Chinese, and Japanese patients. Urologic Oncology: Seminars and Original Investigations. 1:51-63.
    334. Breast cancer. 269-278.
    335. An international ki67 reproducibility study. Journal of the National Cancer Institute. 105:1897-1906.
    336. Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. Genomics Data. 1:7-10.
    337. Breast cancer prognostic and predictive factors. Seminars in Breast Disease. 7:91-100.
    338. Pathology. 633-643.
    339. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Modern Pathology.
    340. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy. Annals of Surgical Oncology. 1-9.
    341. RNA yield from needle biopsies for cDNA microarray analysis of breast cancer prior to neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 69:301.
    342. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Women's Oncology Review. 4:211-212.
    343. Cardiac allograft pathology-A comment on the problem of chronic rejection. Cardiovascular Pathology. 4:223.
    344. Commercialized multigene predictors of clinical outcome for breast cancer (Oncologist (2008) 13, (477-493) DOI. Oncologist. 13:921.
    SYMMANS's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (674)
    Co-Authors (139)
    Similar People (60)
    Same Department Expand Description